General linear mixed model coefficients and significance for species-specific ungulate intensity of use as a function of cattle grazing period. by Kathryn Knodel (20036529)

Estimated marginal mean (± SE) age group differences in the average time on ball performed by professional soccer players on a match day for each position. by Emily Escreet (20552634)

Subjects: “…tailed statistical significance…”

Forest plot for the significant MR association between four mediators and anti-H. pylori IgG seropositivity. by Jing Wang (6206297)

Subjects:

Characterization of miRNA expression profiles and their potential targets upon Bz and Bz + PTX therapy in chronically infected mice. Relative expression was expressed as fold chang... by Glaucia Vilar-Pereira (686134)

Mean concentrations of sum cannabinoids, CBD, Cannabichromene, δ8-Tetrahydrocannabinol, δ9-Tetrahydrocannabinol, and other EO constituents (acid asters, ketone, alcohol) obtained f... by Valtcho D. Zheljazkov (627617)

Primary data. by Andrey V. Cybulsky (4007012)

Subjects:

Effects of bevacizumab addition on VEGF-A concentrations <i>in vitro</i>. by Masashi Okawa (8951294)

Subjects:

The characteristics and clinical features of 12 patients. by Masashi Okawa (8951294)

Subjects:

Effect of adding rhVEGF-A (-121 or -165) on the concentrations of VEGF-A121 and VEGF-A165 in plasma samples. by Masashi Okawa (8951294)

Subjects:

Effect of the VEGF-A–bevacizumab complex removal using immunoprecipitation on the concentrations of VEGF-A121, VEGF-A165, and VEGF-A. by Masashi Okawa (8951294)

Subjects:

Equation of the equilibrium dissociation constant of the antigen-antibody reaction. by Masashi Okawa (8951294)

Subjects:

The original data for the figures. by Masashi Okawa (8951294)

Subjects:

Blood concentrations of VEGF-A121, VEGF-A165, and VEGF-A pre- and post-bevacizumab administration. by Masashi Okawa (8951294)

Subjects:

VEGF-A121, VEGF-A165, and VEGF-A contents per unit platelets. by Masashi Okawa (8951294)

Subjects:

Neutralization with additional bevacizumab to serum samples pre- and post-bevacizumab administration. by Masashi Okawa (8951294)

Subjects:

Hypothetical mechanism by which plasma VEGF-A121 concentration is elevated post-bevacizumab administration. by Masashi Okawa (8951294)

Subjects:

Renal (urea and creatinine) (a, b) and Liver function (ALT and AST) (c, d) test in serums of different experimental groups and body weight changes (e) on day 10. by Omid Mehrpour (9385929)

Subjects:

Significant associations in GWAS. by Dai Nogimura (21445649)

Subjects:

Baseline patient characteristics. by Oscar F. C. van den Bosch (22184246)

Subjects:

Effects of s-ketamine and midazolam on respiratory parameters. by Oscar F. C. van den Bosch (22184246)

Subjects: